Compound Profiles
B7-33
Relaxin-2 Analog | Anti-Fibrotic & Cardiovascular
Selectively activates RXFP1, the primary receptor for relaxin-2, triggering downstream signaling cascades that inhibit fibroblast activation and collagen deposition, promote extracellular matrix remodeling via increased matrix metalloproteinase (MMP) activity, enhance nitric oxide-mediated vasodilation, and reduce inflammatory cytokine expression. B7-33 appears to preferentially engage pERK1/2 signaling pathways while showing reduced cAMP activation compared to native relaxin-2, suggesting biased agonism at RXFP1.
BPC-157
Body Protection Compound-157 | Pentadecapeptide
Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take B7-33 with BPC-157?
Yes, B7-33 and BPC-157 can generally be taken together. No known negative interactions; different mechanisms of action with complementary tissue-repair and anti-fibrotic properties.
Is B7-33 and BPC-157 safe together?
Based on documented research, this combination is considered compatible. However, shared safety flags include: teratogenic. Monitor accordingly.
What are the interactions between B7-33 and BPC-157?
No known negative interactions; different mechanisms of action with complementary tissue-repair and anti-fibrotic properties. This assessment has 90% confidence and is based on documented research data.
How should I time B7-33 and BPC-157?
B7-33 has a half-life of Not well characterized and BPC-157 has a half-life of <30 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.